

**REMARKS**

Applicants hereby amend the Specification to correct clerical errors that were not properly corrected in the Preliminary Amendment dated September 1, 2006. In addition, Applicants hereby replace original Claims 1-17, with new Claims 18-36. Support for the new claims can be found in, but is not limited to, the original claim set and the examples. In particular, experimental Examples 4, 5, and 6 disclose methods for using insulin to suppress adiponectin receptor expression, and methods for preventing insulin-induced suppression of adiponectin receptor expression, respectively. Further support can be found for instance in the summary, which discloses various screening methods (Specification, from page 14, line 7 to page 16, line 29). Thus the amendments do not introduce new matter. However, if the Examiner wishes to discuss this application, the Examiner is encouraged to call the undersigned collect.

Dated: May 8, 2007



---

Christine A. Lekutis  
Registration No. 51,934

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415.904.6500